IQVIA Appoints Richard Staub III President of Research & Development Solutions
26 September 2023 - 10:01AM
Business Wire
IQVIA™ (NYSE:IQV), a leading global provider of advanced
analytics, technology solutions and clinical research services to
the life sciences industry, today announced it has appointed
Richard Staub III, currently senior advisor to the Chairman and
CEO, as president of its Research & Development Solutions
(R&DS) business unit.
Richard is a vastly experienced executive with 34 years in the
life science sector and has held numerous senior executive roles
across multiple contract research organizations. Richard previously
served as the president of the R&DS business unit at IQVIA from
2016 to 2022. Under his exceptional leadership the R&DS
business unit accelerated its growth, recorded consecutive years of
record-breaking backlog, posted industry leading book to bill
ratios and significantly increased R&DS revenues. During his
tenure Richard oversaw the rapid expansion of IQVIA’s clinical
research capabilities and, critically, he successfully led this
business unit through the unprecedented challenges of the COVID-19
global pandemic.
In his role as senior advisor to the Chairman and CEO of IQVIA,
Richard worked closely with the R&DS team and was instrumental
in R&DS’ continued success. He had responsibility for key
customer relationships, provided leadership on critical business
issues and continued to guide the overall strategic direction of
the business.
Costa Panagos will be retiring from the organization after a
24-year career at IQVIA, where he held several positions including
most recently the R&DS business unit leadership role since
2022. IQVIA would like to thank Costa for the contributions he has
made to the R&DS organization over this period.
To learn more about IQVIA, visit IQVIA.com for more
information.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 87,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925707699/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2024 to May 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From May 2023 to May 2024